Bachem Semaglutide: The API Behind Licensed Weight-Loss Medicines

Semaglutide is an active pharmaceutical ingredient (API) manufactured by specialist companies, including Bachem, before being formulated into finished licensed medicines such as Wegovy.
Bachem is a contract development and manufacturing organisation (CDMO); it does not sell medicines directly to patients — it supplies pharmaceutical companies within regulated supply chains.
In the UK, the only semaglutide product licensed for weight management is Wegovy (injection), with Wegovy tablets approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight loss in the UK.
Legitimate semaglutide products for UK patients are manufactured, tested and released according to MHRA standards; finished medicines reach patients through GPhC-registered pharmacies following a clinical prescription.

Bachem is a Swiss pharmaceutical manufacturer that produces semaglutide as an active pharmaceutical ingredient (API) — the purified chemical compound that goes into licensed medicines before they reach a pharmacy shelf. Semaglutide itself is the GLP-1 receptor agonist at the heart of Wegovy, the weekly injection licensed in the UK for weight management. Understanding where the ingredient comes from helps explain why sourcing and supply chain legitimacy matter so much when you are considering treatment. Wegovy is a prescription-only medicine; a GPhC-registered prescriber must assess your suitability before any treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How semaglutide goes from a raw ingredient to the medicine that arrives at your door

Step 1: What Bachem actually makes, and what it doesn't

Bachem AG is a Swiss CDMO with a long track record producing peptide-based APIs for the pharmaceutical industry. Semaglutide is a GLP-1 analogue (a peptide molecule) which sits comfortably within Bachem's manufacturing specialism. Bachem synthesises, purifies and quality-tests the raw compound, then supplies it to pharmaceutical companies as a bulk ingredient.

What Bachem does not do is sell finished medicines, dispense to patients or operate within the UK retail pharmacy system. Its role ends long before a medicine reaches a clinic or a home. People searching for "Bachem semaglutide" are often trying to understand whether a product they have seen online is genuine, or to trace where licensed semaglutide originates. Both are sensible questions.

The NHS's patient information for semaglutide on NHS.uk gives a clear overview of what the finished medicine is and what it does, if you want to start with the basics before going further.

Step 2: How the API becomes a licensed medicine in the UK

Once a pharmaceutical company receives an API from a manufacturer like Bachem, it formulates it into a finished product, combining the active compound with excipients, filling it into a delivery system (a pre-filled pen, or a tablet with an absorption enhancer), and running stability and sterility testing. Novo Nordisk, the maker of Wegovy, then submits a dossier to the MHRA demonstrating safety, quality and efficacy.

The MHRA licenses the finished product, not the raw API in isolation. That means the route from "Bachem makes semaglutide" to "Wegovy is licensed" involves several regulated steps, each with its own quality controls. If any one of those steps is bypassed (for instance, by someone buying bulk peptide online and filling their own pens) the resulting product has no MHRA authorisation and no manufacturing quality assurance. The MHRA has warned publicly about exactly this kind of supply-chain shortcut, particularly as demand for GLP-1 medicines has grown.

For a broader look at how the different semaglutide presentations are licensed and used, the semaglutide overview on this site covers the UK picture in full.

Step 3: What reaches a patient through a legitimate UK pharmacy

A GPhC-registered pharmacy dispenses Wegovy only once a prescriber has assessed your suitability and issued a prescription. The finished pen contains semaglutide that has been through the entire regulated chain: API synthesis, formulation, MHRA batch release, cold-chain distribution, and pharmacy storage. Nothing in that chain is optional.

When a patient orders through a regulated online pharmacy, what actually arrives is unremarkable in the best way, a DPD parcel in plain, unbranded packaging, inside which sits the pen in its original manufacturer's box, cold-packed for transit, with the Patient Information Leaflet included. It looks like any other medicine delivery, which is precisely the point.

If you are thinking about semaglutide for weight management, you can read about how Wegovy works and who it suits before deciding whether a consultation is the right next step. Our clinical team's background and approach are described on our prescribers page if you want to understand who reviews consultations.

Step 4: Why the source of your semaglutide matters for safety

Online searches for APIs or manufacturing companies sometimes reflect a broader anxiety: is the product I'm being offered genuinely what it claims to be? That anxiety is well founded. The MHRA has flagged that counterfeit and unlicensed weight-loss pens have circulated in the UK, some containing substances entirely different from the labelled product.

The only reliable answer is the supply chain itself. Medicines dispensed by a GPhC-registered pharmacy come from the licensed UK supply chain, sourced through authorised distributors from the original manufacturer. You can verify whether any online pharmacy is registered by checking the GPhC pharmacy register directly, every legitimate UK online pharmacy has a premises number listed there.

For people weighing up the cost and access picture, the treatment and pricing information on this site explains what a private prescription through a regulated service involves. If you have questions about specific semaglutide doses or how titration works in practice, the titration journey typically begins with semaglutide 1 as the starting dose, before progressing through semaglutide 2 and semaglutide 3, with some patients eventually reaching semaglutide 5 as their maintenance dose, and the FAQs section is a good starting point for questions about each stage. Worth checking before you proceed anywhere.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions